Abstract
Abstract The evolution of a quinoline based FLAP inhibitor, L-674,636, into a novel quinoline-indole hybrid compound: MK0591, is described. The new series of compounds are more potent, particularly in binding to FLAP, in inhibiting LTB4 biosynthesis in stimulated human PMN, and in the human whole blood assay.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
